What the notice says
On 19 October 2026, CDC posted a Level 1 ("Practice Usual Precautions") travel health notice for Kenya. The Kenyan Ministry of Health has confirmed an imported case of Ebola disease caused by Bundibugyo virus, along with additional epidemiologically linked cases, in Nairobi. Level 1 is the lowest of CDC's three notice tiers; it signals an identified risk that travelers should be aware of, not a recommendation against travel.
Why Bundibugyo virus matters
Bundibugyo virus is one of several orthoebolaviruses that cause Ebola disease. Transmission occurs through direct contact with blood or body fluids of a symptomatic or deceased infected person, or with contaminated surfaces and materials. It is not spread through casual airborne contact. Typical incubation is roughly 2–21 days, and early features are non-specific: fever, severe fatigue, headache, muscle aches, sore throat, followed in some cases by gastrointestinal symptoms and bleeding manifestations.
Importantly, the licensed Ebola vaccines (Ervebo and the Zabdeno/Mvabea regimen) target Zaire ebolavirus only, and cross-protection against Bundibugyo virus is not established. There is no routine pre-travel vaccination for this species, and licensed monoclonal antibody therapies are likewise Zaire-specific. Risk reduction therefore rests on exposure avoidance.
Public-information measures for travelers
- Avoid contact with blood, body fluids, or items that may have contacted them.
- Avoid contact with people who are visibly ill, and avoid funeral or burial practices involving contact with the body of someone who died of Ebola disease.
- Avoid non-essential visits to healthcare facilities in affected areas; healthcare and outbreak-response workers should follow institutional infection-prevention protocols.
- Avoid contact with bats and non-human primates, and with raw or undercooked meat from them.
- Monitor your health for 21 days after departure and seek medical care promptly if fever or other symptoms develop—calling ahead and disclosing your travel history before arriving.
- Expect exit or entry health screening, including temperature checks, at affected airports.
Pharmacist's note: This notice does not change routine pre-travel pharmaceutical planning for Kenya, where malaria chemoprophylaxis, typhoid, hepatitis A, and yellow fever considerations remain the dominant discussion points. Two practical points: first, malaria and Ebola disease share an early febrile presentation, so self-managing a fever abroad without evaluation is unwise—any fever after travel in this region warrants clinical assessment, not self-triage. Second, antipyretics and anti-diarrheals can mask or complicate early assessment; discuss their use with a clinician rather than defaulting to the travel kit. Review your itinerary and vaccination record with a travel health provider or pharmacist well before departure.
Summary for information only; consult CDC's notice and a qualified clinician for individualized advice.